RCAN3 and peripheral arterial disease: qPCR analysis showed a significant decrease in RCAN3 expression in ischemic muscle (Fig. 4a), HSS-ECs (Fig. 4b), HSS-HUVECs (Fig. 4b) and HSS-BMDMs (Fig. 4d) treated with VEGF165b-Ab vs. respective IgG controls, indicating that VEGF165b inhibition decreases RCAN3 expression in experimental PAD models.